Methotrexate Viatris

Methotrexate, the active ingredient in Methotrexate Viatris, is a antimetabolite (folate antagonist) presented as an intravenous solution for intravenous use. It is employed in the management of rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer, and ectopic pregnancy under specialist supervision.

GNH USA supplies Methotrexate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, and distributes through regulated channels to ensure quality‑assured product availability for clinical use in compliance with local regulations.

Methotrexate is an antimetabolite used to modify immune response and inhibit malignant cell proliferation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission. - Non‑Hodgkin lymphoma: suppresses lymphoma growth as part of combination chemotherapy. - Breast cancer: used in high‑dose regimens to enhance cytotoxic effect. - Ectopic pregnancy: terminates trophoblastic tissue when surgery is not preferred.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring early in therapy. - Fatigue: persistent tiredness reported by many patients. - Oral mucositis: painful mouth sores or ulceration. - Cytopenias: reduced white blood cells, red blood cells or platelets. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Severe hepatotoxicity: potential for liver fibrosis or cirrhosis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Life‑threatening infection: due to profound immunosuppression. - Bone marrow failure: aplastic anemia or pancytopenia. - Renal impairment: acute kidney injury from precipitation of drug crystals.

Careful monitoring and patient education are essential when using methotrexate.

- Liver monitoring: perform baseline and periodic liver function tests. - Hematologic monitoring: check complete blood counts regularly. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Folic acid supplementation: administer folic or folinic acid to reduce toxicity. - Renal dose adjustment: modify dose in patients with impaired renal function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate has several drug interactions that may require avoidance or close monitoring.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate toxicity by reducing renal clearance. - Penicillins (e.g., ampicillin): may elevate methotrexate plasma levels. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Warfarin: potentiates anticoagulant effect, requiring INR monitoring. - Oral contraceptives: may reduce methotrexate efficacy, consider alternative contraception.